Zevra Therapeutics, INC 8-K filings

Zevra Therapeutics stockholders elected directors and ratified auditors, but failed to pass a proposal to declassify the Board.

Zevra Therapeutics announced a significant increase in Q1 2026 net revenue to $36.2 million, driven by MIPLYFFA performance and a $50 million portfolio sale, resulting in a strong cash position and debt-free balance sheet.

Zevra Therapeutics has sold its SDX portfolio, including AZSTARYS and KP1077, to Commave Therapeutics for $50 million, simultaneously resolving a pending lawsuit and repaying its $63 million term loan.

Zevra Therapeutics announced the appointment of Timothy Sangiovanni as interim principal financial officer, effective January 1, 2026.

Zevra Therapeutics announced the appointment of Alicia Secor to its Board of Directors and the retirement of Wendy Dixon, PhD, effective December 2, 2025.

Zevra Therapeutics announced the resignation of its Chief Financial Officer, R. LaDuane Clifton, effective December 31, 2025, as the company initiates a search for his successor.

Zevra Therapeutics announced robust third-quarter 2025 financial results, driven by strong MIPLYFFA performance and strategic pipeline advancements.

Zevra Therapeutics announced robust second-quarter 2025 financial results, driven by significant revenue growth and a $150 million Pediatric Rare Disease Priority Review Voucher sale, despite non-cash impairment charges.

Zevra Therapeutics, Inc. successfully elected two Class I directors and ratified Ernst & Young LLP as its independent auditor at its 2025 Annual Meeting, despite an unsuccessful opposition nomination attempt.

Zevra Therapeutics announces strong Q1 2025 financial results, driven by MIPLYFFA sales and the strategic sale of a Pediatric Rare Disease Priority Review Voucher (PRV) for $150 million.

Zevra Therapeutics finalizes the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million, bolstering its financial position.

Zevra Therapeutics announces its fourth quarter and full year 2024 financial results, highlighted by $23.6 million in net revenue for the year and the sale of a Priority Review Voucher for $150 million.

Zevra Therapeutics has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million in cash.

Zevra Therapeutics is undergoing organizational changes, including executive departures and a focus on late-stage clinical and commercial opportunities, to accelerate its transformation into a leading rare disease company.

Zevra Therapeutics has announced that MIPLYFFA, the first FDA-approved treatment for Niemann-Pick Disease Type C, is now commercially available in the U.S.

Zevra Therapeutics reports a transformational third quarter, marked by FDA approval of MIPLYFFA, a rare pediatric disease Priority Review Voucher, and a $64.5 million capital raise.

Zevra Therapeutics announced that the FDA has approved MIPLYFFA, the first treatment for Niemann-Pick disease type C, to be used in combination with miglustat.

Zevra Therapeutics reported its second quarter 2024 financial results, highlighted by a favorable FDA advisory committee vote for arimoclomol and a strengthened balance sheet with $113.8 million in pro forma cash.

Zevra Therapeutics has entered into an underwriting agreement to sell 9,230,770 shares of common stock at $6.50 per share, expecting net proceeds of approximately $56.1 million.

Zevra Therapeutics' preliminary Q2 2024 results show a significant revenue decrease compared to the same period last year, primarily due to the absence of a milestone payment.

Zevra Therapeutics announced that the FDA's Genetic Metabolic Diseases Advisory Committee voted favorably that arimoclomol is effective for treating Niemann-Pick disease type C.

Zevra Therapeutics has entered into an agreement to sell up to $75 million of its common stock through an at-the-market offering, while also terminating a previous agreement.

The FDA will convene a meeting with the Genetic Metabolic Diseases Advisory Committee (GeMDAC) on August 2, 2024, to review Zevra Therapeutics' New Drug Application (NDA) for arimoclomol for the treatment of Niemann-Pick disease type C (NPC).

Zevra Therapeutics reported positive final results from its Phase 2 clinical trial of KP1077 for idiopathic hypersomnia, showing the drug was well-tolerated and produced clinically meaningful improvements in patient-reported outcomes.

Zevra Therapeutics held its 2024 Annual Meeting, electing three Class III directors and ratifying Ernst & Young LLP as its auditor, while an amendment to the equity incentive plan was not approved.

Zevra Therapeutics reported its Q1 2024 financial results, highlighted by the full commercial launch of OLPRUVA and progress in its other key programs.

Zevra Therapeutics has entered into a $100 million senior secured loan agreement to refinance existing debt and fund the development and commercialization of its key drug candidates.

Zevra Therapeutics reported its Q4 and full year 2023 financial results, announced a restatement of prior financial statements due to accounting errors, and highlighted positive clinical trial data for KP1077.

Zevra Therapeutics reports positive top-line data from its Phase 2 clinical trial of KP1077 for Idiopathic Hypersomnia, showing clinically meaningful improvements in key symptoms and supporting progression to a Phase 3 trial.

Zevra Therapeutics, Inc. has released an investor presentation to be used in meetings with investors.